BioConsortia has raised $15 Million in New Funding

According to filings with the U.S. Securities and Exchange Commission, BioConsortia has raised $15 Million in new Series G funding. The federal securities law requires the notice to be filed by...

Craig Etkin

November 13, 2026 2 Min Read

56 0

According to filings with the U.S. Securities and Exchange Commission, BioConsortia has raised $15 Million in new Series G funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Otter Capital

About BioConsortia
BioConsortia is a microbial technology company developing biological crop inputs by turning microbial discoveries into practical agricultural solutions. Its proprietary research and development platform combines microbial discovery, microbe visualization and genetic optimization to create stable, high-performing products. Built around Gram-positive, spore-forming microbes, the platform supports consistent performance at scale, rapid pipeline development and collaboration with partners. The companys portfolio includes nitrogen-fixation, biocontrol and biostimulant products designed primarily for seed application. Its field-validated products are intended to improve crop performance, resilience and input efficiency, with commercialization pursued through strategic partners and select market channels. BioConsortia works with global and regional industry leaders and biotech investors and is supported by a team of scientists, researchers and agricultural business leaders.

To learn more, visit https://www.bioconsortia.com/
Linkedin: https://www.linkedin.com/company/bioconsortia-inc-/

Contact:
Marcus Meadows-Smith, CEO
https://www.linkedin.com/in/marcus-meadows-smith-458abb3/